FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

被引：0
|
作者：
Daneshmand, Siamak
van der Heijden, Michiel S.
Jacob, Joseph M.
Necchi, Andrea
Xylinas, Evanguelos
Morris, David S.
Spiegelhalder, Philip
Zainfeld, Daniel
Kang, Taek Won
Matulay, Justin T.
Belkoff, Laurence H.
Decaestecker, Karel
Arentsen, Harm
Hampras, Shalaka
Jin, Shu
Cutie, Christopher J.
Sweiti, Hussein
Stromberg, Katherine
Martin, Jason
Simone, Giuseppe
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
LBA02-03
引用
收藏
页码：E1187 / E1187
页数：1
相关论文
共 50 条
  • [11] Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non-muscle-invasive bladder cancer: A phase 1 study.
    van Valenberg, F. Johannes P.
    van der Heijden, Toine
    Cutie, Christopher
    Bhanvadia, Sumeet Kaur
    Keegan, Kirk A.
    Hampras, Shalaka
    Sweiti, Hussein
    Maffeo, John
    Jin, Shu
    Chau, Albert
    Reynolds, Don
    Iarossi, Crysti
    Kelley, April
    Li, Xiang
    Stromberg, Katherine
    Sedelaar, Michiel
    Steenbruggen, Jessica
    Somford, Diederik Meindert
    Witjes, Alfred Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [12] SUNRISE-2: A PHASE 3, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY OF TAR-200 IN COMBINATION WITH CETRELIMAB VERSUS CONCURRENT CHEMORADIOTHERAPY IN PARTICIPANTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
    Williams, Stephen
    Cutie, Christopher
    Keegan, Kirk
    Raybold, Bradley
    Stewart, Rachel
    Acharya, Milin
    Zhu, Wei
    Li, Xiang
    O'Dondi, Lang
    Beeharry, Neil
    Spratt, Daniel
    JOURNAL OF UROLOGY, 2021, 206 : E250 - E250
  • [13] A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder.
    Williams, Stephen B.
    Cutie, Christopher
    Keegan, Kirk A.
    Raybold, Bradley
    Acharya, Milin
    Zhu, Wei
    Li, Xiang
    O'Dondi, Lang A.
    Beeharry, Neil
    Spratt, Daniel Eidelberg
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [14] SUNRISE-5: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF TAR-200 COMPARED WITH INTRAVESICAL CHEMOTHERAPY AFTER BACILLUS CALMETTE-GUERIN IN RECURRENT HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Sima, Porten
    Sumeet, Bhanvadia
    Saltanat, Najmi
    Hussein, Sweiti
    John, Maffeo
    Kate, Stromberg
    Jovita, Gale
    Benjamin, Pradere
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [15] TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
    Necchi, A.
    Guerrero-Ramos, F.
    Crispen, P. L.
    Imbroda, B. Herrera
    Garje, R.
    Powles, T. B.
    Peyton, C. C.
    Pradere, B.
    Ku, J. H.
    Shore, N. D.
    Boegemann, M.
    Preston, M. A.
    Xylinas, E.
    Gong, C.
    Najmi, S.
    Hasan, M.
    Stitou, H.
    Bhanvadia, S.
    Sweiti, H.
    Psutka, S. P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1271 - 1272
  • [16] Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer
    Hannouneh, Zein Alabdin
    Hijazi, Amjad
    Alsaleem, Alaa Aldeen
    Hami, Siwan
    Kheyrbek, Nina
    Tanous, Fadi
    Khaddour, Karam
    Abbas, Abdulfattah
    Alshehabi, Zuheir
    CANCER MEDICINE, 2023, 12 (24): : 21944 - 21968
  • [17] The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
    Daneshmand, Siamak
    Brummelhuis, Iris S. G.
    Pohar, Kamal S.
    Steinberg, Gary D.
    Aron, Manju
    Cutie, Christopher J.
    Keegan, Kirk A.
    Maffeo, John C.
    Reynolds, Donald L.
    Raybold, Bradley
    Chau, Albert
    Witjes, J. Alfred
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 344.e1 - 344.e9
  • [18] The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
    van Valenberg, F. Johannes P.
    van der Heijden, Antoine G.
    Cutie, Christopher J.
    Bhanvadia, Sumeet
    Keegan, Kirk A.
    Hampras, Shalaka
    Sweiti, Hussein
    Maffeo, John C.
    Jin, Shu
    Chau, Albert
    Reynolds, Donald L.
    Iarossi, Crysti
    Kelley, April
    Li, Xiang
    Stromberg, Katharine A.
    Sedelaar, J. P. Michiel
    Steenbruggen, Jessica J. O.
    Somford, Diederik M.
    Witjes, J. Alfred
    EUROPEAN JOURNAL OF OPERATIONAL RESEARCH, 2024, 62 (01) : 8 - 15
  • [19] Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
    Jacob, Joseph M.
    Guerrero-Ramos, Felix
    Xylinas, Evanguelos
    Simone, Giuseppe
    Lotan, Yair
    Pieczonka, Christopher Michael
    Arentsen, Harm
    Necchi, Andrea
    Kulkarni, Girish S.
    Patel, Manish
    Cahn, David J.
    Nam, Jong Kil
    Boegemann, Martin
    Hampras, Shalaka
    Stromberg, Katherine
    Martin, Jason L.
    Shulka, Abhijit
    Sweiti, Hussein
    Van Der Heijden, Michiel Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 701 - 701
  • [20] An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer
    Khene, Zine-Eddine
    Lotan, Yair
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (06) : 415 - 423
12345